TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02978118

Intervention type: DEVICE
Intervention: Immune cell and CTC detection procedures
Description: Immune cell profiling assays (in blood and archival tumor samples) and circulating tumor cell assays (in blood samples)

Intervention type: DEVICE
Intervention: Immune cell and CTC detection procedures
Description: Immune cell profiling assays (in blood and archival tumor samples) and circulating tumor cell assays (in blood samples)
Study: NCT03693638

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-fentanyl
Description: 2,5 ml total anesthetic drug dose were given with 0.2 ml/second rate, and subjects were asked to remain sitted for 90 seconds

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-fentanyl
Description: 1,5 ml of total anesthetic drug dose followed by 1 ml remaining dose after 90 s interval were given
Study: NCT00772876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P1446A-05
Description: P1446A-05 capsules will be given once daily for 28 days in each 28 day cycle for 4 such cycles. The starting dose, for first cohort will be 75 mg once daily. Subsequent cohorts of patients will receive higher doses till the recommended phase II dose is identified.
Study: NCT00932048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 10mg once daily for 12 weeks
Study: NCT01585051

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 25(OH) vitamin D
Description: 300 000 U intramuscularly, one dosage, in subjects with 25 (OH) vit D levels below 80 nmol/L, another dosage of 150 000 U after 3 months if 25(OH)vit D levels continue to be below 80 nmol/L.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9 % NaCl
Description: 1 ml of 0.9 % of NaCl at the beginning and 0.5 ml of 0.9 % NaCl after three months
Study: NCT04394780

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cooling
Description: First, patients underwent peritoneal dialysis (PD) at 37 C (standard temperature) and then patients underwent PD cooling. After each PD session, the patient had a CT scan for the study team to study myocardial perfusion at rest and after introduction of a pharmacological stressor.
Study: NCT02767011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-Health Electronic Monitoring (THEM)
Description: Patients in the intervention group (THEM) will receive a tablet computer and home monitoring medical devices with sensors to transmit the information to a central website that will be monitored by care managers. Medical devices will include weight scales, blood pressure cuffs and blood glucometers. Clinical care mangers will remotely monitor the patients and all electronic readings. Clinical care managers will call or send text messages to the patients based on alerts generated by the tele-health monitoring system.
Study: NCT01850238

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AADvac1
Description: AADvac1 is intended as an active vaccination for disease-modifying treatment of Alzheimer's disease.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo contains the same buffer and adjuvant as AADvac1, but lacks the API.
Study: NCT04446169

Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV 2 RNA PCR Urine
Description: Search for SARS-CoV 2 RNA in urine through PCR

Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV 2 RNA PCR Semen
Description: Search for SARS-CoV 2 RNA in Semen through PCR

Intervention type: DIAGNOSTIC_TEST
Intervention: Semen Qualitative Analysis
Description: Search for Semen Alterations in patients with past SARS-CoV 2 infection
Study: NCT02399982

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CBT-GSH
Description: The treatment will be based on Overcoming Binge Eating. The treatment is divided into a user-friendly section on binge eating and a six-step self-help program. The first session will last 60 min, with each subsequent section lasting 20-25 minutes in length. Sessions are weekly over 3 months. Working with the therapist, participants will use the self-help guide to develop regular and moderate eating using selfmonitoring, problem solving, and other CBT techniques.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CBT-GSH
Description: The treatment will be based on Overcoming Binge Eating. The treatment is divided into a user-friendly section on binge eating and a six-step self-help program. The first session will last 60 min, with each subsequent section lasting 20-25 minutes in length. Sessions are weekly over 3 months. Working with the therapist, participants will use the self-help guide to develop regular and moderate eating using selfmonitoring, problem solving, and other CBT techniques.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Noom Monitor
Description: This treatment will be exactly the same as CBT-GSH with the exception that all self-monitoring will be conducted through Noom Monitor and individuals will receive a specialized set of instructions on how to use the monitor. Therapists will also be asked to check feedback report on clients before each session. Therapists will receive weekly letter grades regarding each patient based on weekly level of OBEs/Purging, treatment adherence, and weekly weighing.
Study: NCT04446169

Intervention type: DIAGNOSTIC_TEST
Intervention: IIEF-5 questionnaire
Description: IIEF-5 assessment in patients with past SARS-CoV 2 infection
Study: NCT03184519

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pregnancy test
Description: Instead of one blood sample, patients will have three blood analyses to predict pregnancy earlier after the embryo transfer.
Study: NCT04446169

Intervention type: DIAGNOSTIC_TEST
Intervention: Male Sexual Health Questionnaire (MSHQ)
Description: Male Sexual Health Questionnaire (MSHQ) assessment in patients with past SARS-CoV 2 infection

Intervention type: DIAGNOSTIC_TEST
Intervention: IPSS questionnaire
Description: IPSS assessment in patients with past SARS-CoV 2 infection

Intervention type: DIAGNOSTIC_TEST
Intervention: SECRET questionnaire
Description: SECRET questionnaire assessment in patients with past SARS-CoV 2 infection

Intervention type: DIAGNOSTIC_TEST
Intervention: Interleukin assessment in semen
Description: Assessment of Interleukin presence and quantitative analysis in semen, to study if a previous inflammation/infection due to SARS-CoV 2 in testis was present
Study: NCT02917083

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CAR T Cells
Description: Three dose levels will be evaluated based on safety data from our current study of CD30 CAR T cells. Cohorts of three to six patients will be enrolled at each dose level. Each patient will receive one infusion of CAR modified T cells according to the following dosing schedule:~Dose Level One: 2x10\^7 cells/m2. Dose Level Two: 1x10\^8 cells/m2. Dose Level Three: 2x10\^8 cells/m2.
Study: NCT03265262

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: The basophil activation test (BAT)
Description: Single sample: 5 mL of venous blood
Study: NCT01554462

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Eicosapentaenoic acid / Docosahexaenoic acid
Description: 650 mg EPA + 650 mg DHA daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo dietary intervention (MUFA) in ADHD group
Description: Placebo contains mono-unsaturated fatty acids (MUFA) in stead of poly-unsaturated fatty acids (PUFA), same energy value
Study: NCT01615731

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 400mcg buccal misoprostol 90 minutes pre-op

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-amniotic digoxin
Description: 1mg digoxin administered intra-amniotically \~24 hours pre-op

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra-amniotic digoxin
Description: 1mg digoxin administered intra-amniotically \~24 hours pre-op
Study: NCT01772433

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive oil
Description: Phonophoresis with Olive oil for 10 day, daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phonophoresis gel
Description: Phonophoresis with base gel for 10 days, daily
Study: NCT04543123

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS treatment
Description: Participants visited the hospital four times (biweekly for two weeks). During their second visit, a research nurse instructed each participant on use of home-based tDCS equipment (YDS-301N; Ybrain Inc., Seongnam-si, Korea) and all participants thereafter conducted tDCS treatment at home once a day for 30 minutes (five times per week).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS treatment
Description: Participants visited the hospital four times (biweekly for two weeks). During their second visit, a research nurse instructed each participant on use of home-based tDCS equipment (YDS-301N; Ybrain Inc., Seongnam-si, Korea) and all participants thereafter conducted tDCS treatment at home once a day for 30 minutes (five times per week).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant Drug(escitalopram)
Description: Participants in both active and sham groups were prescribed escitalopram in combination with tDCS treatment.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Antidepressant Drug(escitalopram)
Description: Participants in both active and sham groups were prescribed escitalopram in combination with tDCS treatment.
Study: NCT03998423

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant
Description: Double-encapsulated Fecal Microbiota Transplant Capsules

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant
Description: Double-encapsulated Fecal Microbiota Transplant Capsules

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant
Description: Double-encapsulated Fecal Microbiota Transplant Capsules
Study: NCT02658643

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous suture technique
Description: The BDA is performed as continuous suture with two separate all-layer suture for the behind - and front-wall of the anastomosis
Study: NCT03282877

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCST web-application
Description: The iCST web-application will be delivered by a carer in regular contact with the person with dementia (family carer, a close friend, or a volunteer befriender) for 1.5 hours a week. It is up to the carer to distribute the time in a matter that is convenient to them (e.g. two long sessions of 45 minutes or 3 shorter sessions of 30 minutes). Participants will be asked to use the web-application for a duration of 11 weeks at their homes. Each session will consist of structured cognitive stimulation aided by the use of multimedia. After completing each session, participants will be guided to a new screen on the web-application in which they will be asked to briefly reflect on the session and provide us with feedback.
Study: NCT04405206

Intervention type: PROCEDURE
Intervention: DRE-Endoscopy-MRI-CEA
Description: examination process in follow up

Intervention type: PROCEDURE
Intervention: DRE-Endoscopy-MRI-CEA
Description: examination process in follow up
Study: NCT02658643

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interrupted suture technique
Description: The BDA is performed as interrupted suture with two separate all-layer suture for the behind - and front-wall of the anastomosis
Study: NCT00672048

Intervention type: OTHER
Group type: OTHER
Intervention: Computer Tablet
Description: A tablet computer based software application designed to collect structured clinical information from providers and patients at the point of care.

Intervention type: OTHER
Group type: OTHER
Intervention: Continuing Education Course
Description: Annual standard continuing education
Study: NCT04405206

Intervention type: PROCEDURE
Intervention: Nonoperative Management
Description: Watch and Wait

Intervention type: PROCEDURE
Intervention: Nonoperative Management
Description: Watch and Wait

Intervention type: PROCEDURE
Intervention: Local excision
Description: For ymriT1N0 and near-cCR patients，LE is optional.

Intervention type: PROCEDURE
Intervention: Total Mesorectal Excision
Description: Standard TME surgery openly or laporoscopically

Intervention type: BEHAVIORAL
Intervention: Quality of Life Questionnaires
Description: QLQ C30 and QLQ CR29
Study: NCT00672048

Intervention type: OTHER
Group type: OTHER
Intervention: Continuing education
Description: Annual standard continuing education materials
Study: NCT03895424

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IFAC
Description: This intervention will contain the iron fatty acid complex in a capsule. The complex will be labelled with the iron isotope 58Fe

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MIFAC
Description: This intervention will contain the micellarized form of the iron fatty acid complex in a capsule. The complex will be labelled with the iron isotope with 57Fe

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control Ferrous Sulfate
Description: This intervention will contain ferrous sulfate in the form of a solution labelled with the iron isotope 54Fe. A capsule with the same amount of fat as in the other arms will be administered to the participants
Study: NCT03249922

Intervention type: DEVICE
Intervention: Spinal Cord Stimulation
Description: Implantation of a spinal cord stimulator for the control of axial back or neuropathic pain.
Study: NCT04405206

Intervention type: BEHAVIORAL
Intervention: Quality of Life Questionnaires
Description: QLQ C30 and QLQ CR29

Intervention type: BEHAVIORAL
Intervention: Quality of Life Questionnaires
Description: QLQ C30 and QLQ CR29
Study: NCT02896660

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActiGraph Link
Description: Subjects will be asked to wear the actigraph continuously for a 90-day period, and visit a clinician on day 30, 60, and 90 of the study for data collection.
Study: NCT02951663

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein
Study: NCT03574246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chlorhexidine gluconate %0,12 benzydamine hydrochloride %0,15
Description: chlorhexidine gluconate + benzydamine hydrochloride oral rinse

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: %0.9 NaCl Solution
Description: isotonic sodium chloride
Study: NCT01401920

Intervention type: OTHER
Intervention: leg elevation
Description: bilateral passive leg elevation for 30 seconds

Intervention type: OTHER
Intervention: Trendelenburg position
Description: Trendelenburg position (15 degrees) for 30 seconds

Intervention type: OTHER
Intervention: Trendelenburg position + passive leg elevation
Description: Trendelenburg position + passive leg elevation

Intervention type: OTHER
Intervention: control group
Description: supine position without passive leg elevation or trendelenburg position
Study: NCT00359229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: Administration of Zolpidem 5mg
Study: NCT03280537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Participants received omalizumab as a subcutaneous injection once every 2 weeks (q2w) or once every 4 weeks (q4w). The dose (from 75 mg up to 600 mg) and dosing frequency (q2w or q4w) was determined by serum total IgE level and body weight using the study-drug dosing table.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received matching placebo as a subcutaneous injection once every 2 weeks or once every 4 weeks. The dose and dosing frequency was determined by serum total IgE level and body weight using the study-drug dosing table.
Study: NCT05547815

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 5 doses program
Description: Inoculate 5 doses of rabies vaccine, and collect blood at fixed time points to detect neutralizing antibody
Study: NCT01860391

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diammine Silver Fluoride
Description: Diammine SIlver Fluoride will be applied to teeth. The levels of silver and fluoride in saliva will be measure up to 7 days
Study: NCT04676932

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nursing Care Based on Kolcaba's Comfort Theory
Description: In this study, Nursing care based on Kolcaba's Comfort Theory will be applied for women undergoing HSG.
Study: NCT03476356

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral clomiphene citrate
Description: oral clomiphene citrate 50 mg tablet, two times per day will be received from the third day of the cycle until the seventh day of the cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral clomiphene citrate
Description: oral clomiphene citrate 50 mg tablet, two times per day will be received from the third day of the cycle until the seventh day of the cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral carnitine supplementation
Description: oral carnitine supplementation 1g tablet, three times per day will be received from the third day of the cycle until the day of the pregnancy test.
Study: NCT04200703

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adult and Child Survivor Centered Approach
Description: Child welfare workers and supervisors, and community partners will be trained in the Adult and Child Survivor Centered Approach, and supervisors will receive ongoing coaching and training.
Study: NCT03082456

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Molecular breast imaging
Description: Molecular breast imaging will be performed at 5-10 minutes after intravenous injection of 15-20 millicurie (mCi) Tc-99m sestamibi. Both craniocaudal (CC) view and mediolateral oblique (MLO) images of the breast are taken.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Mammography
Description: During the procedure, the breast is compressed using a dedicated mammography unit. Parallel-plate compression evens out the thickness of breast tissue to increase image quality by reducing the thickness of tissue that x-rays must penetrate, decreasing the amount of scattered radiation, reducing the required radiation dose, and holding the breast still (preventing motion blur). Both craniocaudal (CC) view and mediolateral oblique (MLO) images of the breast are taken.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Breast ultrasound
Description: Ultrasound investigation of breast is performed by members of breast cancer team. If abnormality is found by the procedure, biopsy will not be performed directly.
Study: NCT03483181

Intervention type: DRUG
Intervention: Xarelto (rivaroxaban)
Description: An oral anticoagulant medication for the prevention of VTE (Venous thromboembolism) related to orthopedic surgery. Patients received rivaroxaban during one day prior to or two days after orthopedic surgery during the hospitalization.

Intervention type: DRUG
Intervention: Lovenox (enoxaparin)
Description: An injectable anticoagulant medication for the prevention of VTE (Venous thromboembolism) related to orthopedic surgery. Patients received enoxaparin during one day prior to or two days after orthopedic surgeries during the hospitalization.
Study: NCT01671384

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproate, Levocarnitine
Description: All patients with diagnosis of SMA aged 2-15 years already registered in Myopathy Clinic of AIIMS will be recalled. Information will be sent to all Government Hospitals in Delhi that such a study is currently in progress and all the referrals will also be recruited. These patients and all those newly diagnosed at Myopathy Clinic, AIIMS will be randomized into two groups:~Group I (Physiotherapy + Placebos) Group II (Physiotherapy + Valproate and Levocarnitine)~The investigators will be blinded to the code of the medicine. It will be broken only at the end of the study or if there are any significant side effects. So one group will receive Valproate and levocarnitine and other group will receive Placebo and placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All patients with diagnosis of SMA aged 2-15 years already registered in Myopathy Clinic of AIIMS will be recalled. Information will be sent to all Government Hospitals in Delhi that such a study is currently in progress and all the referrals will also be recruited. These patients and all those newly diagnosed at Myopathy Clinic, AIIMS will be randomized into two groups:~Group I (Physiotherapy + Placebos) Group II (Physiotherapy + Valproate and Levocarnitine)~The investigators will be blinded to the code of the medicine. It will be broken only at the end of the study or if there are any significant side effects. So one group will receive Valproate and levocarnitine and other group will receive Placebo and placebo.
Study: NCT01875445

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inositol
Description: Taken as 2g of powder TID for 2 weeks, then 4g of powder TID for 2 weeks and then 6g of powder TID for the remainder of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taken as 2g of powder TID for 2 weeks, then 4g of powder TID for 2 weeks and then 6g of powder TID for the remainder of the study.
Study: NCT04823000

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells (MSC)
Description: Repeated intrathecal and intravenous injection of autologous mesenchymal stem cells (1 million cells per Kg of body weight) at 6 months intervals.
Study: NCT03306056

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Individualized, weight-reducing nutritional therapy and counseling, during a study period of 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Strength Training
Description: Procedures: Nutritional therapy (individualized, weight-reducing nutritional therapy and counseling) during a study period of 12 weeks combined with a standard strength training program:~* 5 strength training exercises (chest, upper/lower back, abdominals, legs)~* 3 sets per exercise~* time-effort per session: \~90 min~* 2 training sessions per week~* duration of exercise intervention: 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-volume Strength Training
Description: Procedures: Nutritional therapy (individualized, weight-reducing nutritional therapy and counseling) during a study period of 12 weeks combined a low-volume strength training program:~* 5 strength training exercises (chest, upper/lower back, abdominals, legs)~* 1 set per exercise~* time-effort per session: \~20 min~* 2 training sessions per week~* duration of exercise intervention: 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-Body Electromyostimulation (WB-EMS)
Description: Procedures: Nutritional therapy (individualized, weight-reducing nutritional therapy and counseling) during a study period of 12 weeks combined with WB-EMS:~* time-effort per session: \~20 min~* duration of exercise intervention: 12 weeks